Brief: Neurobo Pharmaceuticals Doses First Patient In Its Phase 2A Clinical Trial Evaluating Da-1241

MetaVia

15/09/2023 14:14

Sept 15 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS DOSES FIRST PATIENT IN ITS PHASE
2A
CLINICAL TRIAL EVALUATING DA-1241 FOR THE TREATMENT OF NASH
    * NEUROBO PHARMACEUTICALS INC - FULL DATA READOUT EXPECTED
IN
SECOND HALF OF 2024
    * NEUROBO PHARMACEUTICALS INC- FULL DATA READOUT EXPECTED IN
SECOND HALF OF 2024
    * NEUROBO PHARMACEUTICALS INC - TWO-PART DESIGN PROVIDES
OPTIONALITY FOR INTERIM ANALYSIS IN FIRST HALF OF 2024

Source text for Eikon:  ID:nPnbPkhwba 
Further company coverage:  NRBO.O 

 ((reuters.briefs@thomsonreuters.com;))